Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 June 2024 | Story André Damons | Photo Suplied
Dr Claudia Ntsapi
Dr Matlakala C Ntsapi is a Senior Lecturer and researcher in the Department of Basic Medical Sciences at the UFS.

A researcher from the University of the Free State (UFS) is investigating the potential benefits of medicinal plants as supplementary treatments for neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Huntington’s diseases.

The work of Dr Matlakala Claudia Ntsapi, Senior Lecturer in the Department of Basic Medical Sciences at the UFS, focuses on preserving human brain health to delay or prevent age-related conditions.

According to her, while the primary focus is on age-related neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s, the bioactive compounds in these medicinal plants may also have therapeutic potential for other neurological disorders, various types of cancers and Type 2 Diabetes. The broad protective effects of these plant-based bioactive compounds could make them relevant in the potential treatment of other diseases involving oxidative stress and inflammation.

She is involved in several multidisciplinary projects, collaborating with research experts from Denmark, the UK, and various national institutions such as the Central University of Technology (CUT), North West University (NWU), and the Stellenbosch University (SUN), as well as colleagues from the UFS. 

The potential of medicinal plants

“In collaboration with experts from our institution, the CUT and SU, who have strong backgrounds in pharmacology and ethnobotany, we are focusing on underexplored medicinal plants and nutraceuticals. These plants contain bioactive compounds with potential neuroprotective properties, which are believed to provide extra health benefits beyond basic nutritional value,” says Dr Ntsapi.

“We hope that these medicinal plants have the potential to preserve cognitive function and slow the progression of neurodegenerative diseases like Alzheimer’s. Specifically, we aim to identify novel therapeutic targets and discover new avenues for intervention that can improve the quality of life for individuals affected by age-related brain conditions,” she says.

Identifying therapeutic targets and discovering new interventions

The bioactive compounds found in selective medicinal plants and nutraceuticals, explains Dr Ntsapi, serve as a promising source of ‘natural’ therapeutics that may be safer and have fewer side effects compared to conventional synthetic drugs. Additionally, the untapped potential of these compounds for neuroprotection and the preservation of brain health could provide innovative therapeutic solutions. These compounds may be used as complementary therapies to existing drugs, which often have limited efficacy on their own, thereby enhancing overall treatment outcomes for neurodegenerative diseases.

“By utilising cutting-edge techniques, such the innovative CelVivo ClinoStar 2 System, we strive to gain insights into the safety and efficacy of underexplored medicinal plants in preserving cognitive function and slowing disease progression.

“By exploring the untapped potential of bioactive compounds found in medicinal plants and nutraceuticals, our research group aims to contribute to the identification of novel therapeutic targets and the discovery of new avenues for intervention to improve the quality of life for individuals affected by age-related brain conditions,” says Dr Ntsapi.

The researchers, in collaboration with others in the UFS School of Clinical Medicine, will develop 3D cell-based models of the human cortex and hippocampus by utilising the CelVivo ClinoStar 2 System. This cutting-edge technology, housed in an easy-to-use CO² incubator, mimics ‘animal model-like’ conditions with low sheer stress, allowing scientists to generate cell-based models that closely resemble real-world conditions.

Dr Ntsapi explains that they will specifically focus on the technologies’ applications in studying age-related neurodegenerative disorders, such as Alzheimer’s disease. The potential impact of this research is immense, as it could contribute to the development of novel therapeutic strategies for combating the debilitating progression of neurodegenerative diseases, and ultimately improving the quality of life for affected individuals.

Hope for the research

“Our hope for this research is to significantly advance our understanding of neurodegenerative disease progression and to develop novel therapeutic strategies that can effectively combat these debilitating conditions. Ultimately, we aim to improve the quality of life for individuals affected by neurodegenerative diseases by preserving cognitive function and slowing disease progression.

“This research will contribute to the knowledge pool in this field, with the potential to lead to groundbreaking discoveries in the treatment of Alzheimer’s disease and other related disorders, potentially contributing to the policy guidelines on how these conditions are managed and treated,” she says.

The international partners from Denmark and the UK have made their expertise and facilities available to postgraduate students from the UFS, some of whom they are co-supervising.

Dr Ntsapi, who is passionate about exploring innovative solutions to address the gradual decline in normal brain function associated with aging, was this year one the university’s nominations for the prestigious 2023/2024 NSTF-South32 Awards, popularly known as the “Science Oscars” of South Africa. 

News Archive

Provisional registration period extended to 30 April 2012
2012-03-25

25 March 2012

After a week of intense negotiations between the senior leadership of the University of the Free State (UFS) and the Student Representative Council (SRC) of the Bloemfontein and Qwaqwa Campuses, the SRC has managed to persuade the senior leadership to extend the provisional registration period to Monday 30 April 2012.

This means that, until 30 April 2012, no students will be deregistered for not being able to pay their provisional registration fee. The initial deadline for students to register provisionally was 6 April 2012.

The SRC requested the extension of provisional registration and the senior leadership of the UFS agreed thereto for the following reasons:

  • To allow students more time to raise the money;
  • To allow the provincial and national government, as well as NSFAS more time to respond to students’ financial needs; and
  • To allow the SRC and the university more time to consult with students with strong academic records about financial aid options outside the university.

“The SRC is glad to note that the university management values our efforts in representing our students and we've been able to leverage that advantage to negotiate an extension of the deregistration date with management. We're happy that in this case management has responded to the appeal of students through the SRC and we're exceptionally proud of our ability to push student interests to unprecedented heights,” says Mr Richard Chemaly, SRC President of the Bloemfontein Campus.

According to Mr Chemaly, the SRC is confident in their negotiation abilities. “While others might strike and protest, it is in the best interests of our students to talk to the senior leadership about important issues that are in the interests of students,” he says.

“Since our request to extend the provisional registration period was approved by the university management, the SRC has been working tirelessly to ensure that no deserving student gets deregistered. This includes setting up external funds, approaching the Premier’s office for assistance and setting up the most extensive bursary database any SRC has ever had,” Mr Chemaly says.

If there are any parents or students in need of help for provisional registration, please contact Mr Chemaly at  chemalyra@ufs.ac.za.
 

Media Release
25 March 2012
Issued by: Lacea Loader
Director: Strategic Communication
Tel: +27(0)51 401 2584
Cell: +27(0)83 645 2454
E-mail: news@ufs.ac.za

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept